Stem Cell Therapy for Parkinson - Current... - Cure Parkinson's

Cure Parkinson's

26,357 members27,731 posts

Stem Cell Therapy for Parkinson - Current trials Patients experiences

Farooqji profile image
2 Replies

Co-organized by ISSCR and the WPC, this open access webinar will provide a high-level outlook of current cell therapy research and clinical applications for Parkinson’s disease. Presenters will highlight advances in cell and gene therapies, including basic research discoveries and the latest clinical trials. Attendees will hear a first-hand account of the journey to receive a gene therapy from a person living with Parkinson’s disease. The program is geared to researchers across the stem cell field who will gain understanding of the newest research advances and enhance their knowledge of patient perspectives and to people with Parkinson’s disease and their caregivers who will learn the progress toward novel cell and gene therapy development and have the opportunity to ask questions of innovative scientists in the field.

Stem Cells and Parkinson’s Disease: Research Advances + Patient Experiences

Oct 21, 2024 11:00 AM EDT

Google Calendar ICS -

healthunlocked.com/redirect...

Written by
Farooqji profile image
Farooqji
To view profiles and participate in discussions please or .
Read more about...
2 Replies
gomelgo profile image
gomelgo

Thank you for posting!

Not what you're looking for?

You may also like...

Stem Cells Trials

I want to make a list here. Please reply with links...

Autologous IP Stem Cell Update

🔬 “Aspen Neuroscience looks to combine its expertise in stem cell biology, genomics and neurology...

Aspen FINALLY Moving forward with Stem Cell Trials

I have been repeatedly writing posts regarding Dr. Jeanne Loring, Aspen Neuroscience, and/or stem...

Stem Cell Human Trials for Macular Degeneration

We aren't there yet with Parkinson's Disease, but I still remain excited about the possibility of...

1Trial of Bradykinesia Stem Cell Therapy Now Dosing Last Group

IMAC Holdings has started dosing the third and final group of participants in a Phase 1 clinical...